| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Christa C van Bunderen, Nadège C van Varsseveld, Martijn W Heymans, Anton A M Franken, Hans P F Koppeschaar, Aart J van der Lely, Madeleine L Dren. Effect of long-term GH replacement therapy on cardiovascular outcomes in GH-deficient patients previously treated for acromegaly: a sub-analysis from the Dutch National Registry of Growth Hormone Treatment in Adults. European journal of endocrinology. vol 171. issue 6. 2015-07-08. PMID:25227133. |
the aim of the study is to describe the characteristics of patients with severe ghd who were previously treated for acromegaly, and to investigate the effects of long-term gh treatment on cardiovascular risk factors and morbidity, compared with patients who were treated for a nonfunctioning pituitary adenoma (nfpa). |
2015-07-08 |
2023-08-13 |
Not clear |
| A J Varewijck, S W J Lamberts, A J van der Lely, S J C M M Neggers, L J Hofland, J A M J L Jansse. The introduction of the IDS-iSYS total IGF-1 assay may have far-reaching consequences for diagnosis and treatment of GH deficiency. The Journal of clinical endocrinology and metabolism. vol 100. issue 1. 2015-07-08. PMID:25337924. |
igf-1 measurements are used for screening and monitoring gh deficiency (ghd) and acromegaly. |
2015-07-08 |
2023-08-13 |
Not clear |
| Sauradeep Sarkar, Ari George Chacko, Geeta Chack. An analysis of granulation patterns, MIB-1 proliferation indices and p53 expression in 101 patients with acromegaly. Acta neurochirurgica. vol 156. issue 12. 2015-07-07. PMID:25238988. |
the authors sought to comprehensively examine clinical and radiological correlates of growth hormone (gh)-secreting pituitary adenomas with regard to several commonly used immunocytochemical techniques in patients undergoing transsphenoidal surgery for acromegaly. |
2015-07-07 |
2023-08-13 |
Not clear |
| Cuiqi Zhou, Yonghui Jiao, Renzhi Wang, Song-Guang Ren, Kolja Wawrowsky, Shlomo Melme. STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion. The Journal of clinical investigation. vol 125. issue 4. 2015-07-02. PMID:25774503. |
pituitary somatotroph adenomas result in dysregulated growth hormone (gh) hypersecretion and acromegaly; however, regulatory mechanisms that promote gh hypersecretion remain elusive. |
2015-07-02 |
2023-08-13 |
human |
| Ruth Mangupli, Paul Camperos, Susan M Web. Biochemical and quality of life responses to octreotide-LAR in acromegaly. Pituitary. vol 17. issue 6. 2015-07-01. PMID:24178448. |
this study was designed to determine acroqol score changes and concentrations of growth hormone (gh) and insulin-like growth factor 1 (igf-1), before and after treatment with octreotide-lar (oct-lar) in acromegaly. |
2015-07-01 |
2023-08-12 |
Not clear |
| Jowita Halupczok-Żyła, Aleksandra Jawiarczyk-Przybyłowska, Marek Bolanowsk. Patients with Active Acromegaly are at High Risk of 25(OH)D Deficiency. Frontiers in endocrinology. vol 6. 2015-06-17. PMID:26082755. |
acromegaly is a chronic disease characterized by hypersecretion of growth hormone (gh) and insulin-like growth factor 1 (igf-1). |
2015-06-17 |
2023-08-13 |
human |
| S V Lim, M Marenzana, M Hopkinson, E O List, J J Kopchick, M Pereira, B Javaheri, J P Roux, P Chavassieux, M Korbonits, C Chen. Excessive growth hormone expression in male GH transgenic mice adversely alters bone architecture and mechanical strength. Endocrinology. vol 156. issue 4. 2015-06-11. PMID:25646711. |
patients with acromegaly have a higher prevalence of vertebral fractures despite normal bone mineral density (bmd), suggesting that gh overexpression has adverse effects on skeletal architecture and strength. |
2015-06-11 |
2023-08-13 |
mouse |
| Lucia Schwyzer, Robert M Starke, John A Jane, Edward H Oldfiel. Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly. Journal of neurosurgery. vol 122. issue 4. 2015-06-03. PMID:25423276. |
the goals of this study were to examine the relationship between tumor volume, growth hormone (gh), and insulin-like growth factor-1 (igf-1) levels, and to assess the correlation between percent tumor removal and the reduction in plasma gh and igf-1 in patients with acromegaly. |
2015-06-03 |
2023-08-13 |
Not clear |
| Cheng Huan, Guihua Cui, Chao Lu, Xin Qu, Tao Ha. Role of Ki-67 in acromegalic patients with hyperprolactinemia: retrospective analysis in 61 Chinese Patients. Pakistan journal of pharmaceutical sciences. vol 28. issue 2 Suppl. 2015-06-01. PMID:25796164. |
patients with higher ki-67 value harbored longer time interval, more aggressive tumors, more acromegaly manifestations, higher gh level, and higher recurrence than patients with lower ki-67 value. |
2015-06-01 |
2023-08-13 |
Not clear |
| Zenei Arihara, Kanako Sakurai, Rika Yamashita, Satsuki Niitsuma, Takayuki Ueno, Nao Yamamura, Shozo Yamada, Naoko Inoshita, Kazuhiro Takahash. Bromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly. The Tohoku journal of experimental medicine. vol 234. issue 2. 2015-05-20. PMID:25253414. |
bromocriptine, a potent d2-dopamine agonist, suppresses growth hormone (gh) secretion in most patients with acromegaly and has been approved for the treatment of acromegaly. |
2015-05-20 |
2023-08-13 |
Not clear |
| Zenei Arihara, Kanako Sakurai, Rika Yamashita, Satsuki Niitsuma, Takayuki Ueno, Nao Yamamura, Shozo Yamada, Naoko Inoshita, Kazuhiro Takahash. Bromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly. The Tohoku journal of experimental medicine. vol 234. issue 2. 2015-05-20. PMID:25253414. |
here we report a patient with acromegaly who showed increased gh secretion after administration of bromocriptine. |
2015-05-20 |
2023-08-13 |
Not clear |
| I A Ilovaĭskai. [Colorectal neo- and dysplasia in acromegaly]. Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology. issue 7. 2015-04-28. PMID:25842403. |
colorectal disorders can be not only an independent disease, but also manifestation of acromegaly--a neuroendocrine disease which is characterized by chronic pathological hypersecretion of the growth hormone (gh) and the increased concentration of insulino-like growth factor type 1 (igf-1). |
2015-04-28 |
2023-08-13 |
Not clear |
| Pinaki Dutta, Saurabh Singhal, Naresh Kumar Sachdeva, Viral N Shah, Ashish Pathak, K K Mukherjee, Anil Bhansal. Diagnostic utility of serum GH, IGF-1 and IGFBP3 in patients of acromegaly with uncontrolled diabetes: a pilot study. The Journal of the Association of Physicians of India. vol 62. issue 8. 2015-04-24. PMID:25856936. |
diagnostic utility of serum gh, igf-1 and igfbp3 in patients of acromegaly with uncontrolled diabetes: a pilot study. |
2015-04-24 |
2023-08-13 |
Not clear |
| J Rojo Álvaro, J J Pineda Arribas, E Anda Apiñániz, L Pérez García, J Lafita Tejedor, Ll Forga Llena. [Ectopic acromegaly due to a bronchial carcinoid]. Anales del sistema sanitario de Navarra. vol 36. issue 3. 2015-04-06. PMID:24406372. |
tumours that cause ectopic acromegaly can do so through the secretion of gh or ghrh. |
2015-04-06 |
2023-08-12 |
Not clear |
| Yu Mi Kang, Jong Han Choi, Min Jung Lee, Ari Ahn, Chan Jeoung Park, Kiju Chang, Seyoung Seo, Sun In Hong, Min Seon Ki. Multiple myeloma in a patient with acromegaly. Endocrinology and metabolism (Seoul, Korea). vol 30. issue 1. 2015-04-01. PMID:25491781. |
acromegaly is a slowly progressing condition resulting from excess growth hormone (gh), generally caused by a gh-secreting pituitary adenoma. |
2015-04-01 |
2023-08-13 |
Not clear |
| Sefika Burcak Polat, Nagihan Ugurlu, Reyhan Ersoy, Oguzhan Oguz, Necati Duru, Bekir Caki. Evaluation of central corneal and central retinal thicknesses and intraocular pressure in acromegaly patients. Pituitary. vol 17. issue 4. 2015-02-23. PMID:23912667. |
herein, we aimed to evaluate cct, iop and retinal thickness (rt), and their relationships with serum gh and igf-1 levels and disease duration, in acromegaly patients. |
2015-02-23 |
2023-08-12 |
Not clear |
| Anna Aulinas, María José Ramírez, María José Barahona, Eugènia Mato, Olga Bell, Jordi Surrallés, Susan M Web. Telomeres and endocrine dysfunction of the adrenal and GH/IGF-1 axes. Clinical endocrinology. vol 79. issue 6. 2015-02-19. PMID:23937625. |
to our knowledge, tl dysfunction has not been described in either endogenous hypercortisolism (cushing's syndrome) or acromegaly where excessive amounts of gh and consequently igf-1 are produced. |
2015-02-19 |
2023-08-12 |
Not clear |
| Maria Fleseri. Advances in the pharmacotherapy of patients with acromegaly. Discovery medicine. vol 17. issue 96. 2015-02-13. PMID:24979253. |
acromegaly is a disease characterized by growth hormone (gh) excess originating, in approximately 95% of cases, from a somatotroph pituitary adenoma. |
2015-02-13 |
2023-08-13 |
Not clear |
| Pinaki Dutta, Bhuvanesh Mahendran, K S Reddy, Jasmina Ahluwalia, Kim Vaiphei, R K Kochhar, Prakamya Gupta, Anand Srinivasan, Mahesh Prakash, Kanchan Kumar Mukherjee, V N Shah, Girish Parthan, Anil Bhansal. Short-term efficacy of recombinant human GH therapy in cured acromegaly patients with GH deficiency: a single-center experience. Endocrine connections. vol 4. issue 1. 2015-02-10. PMID:25600246. |
short-term efficacy of recombinant human gh therapy in cured acromegaly patients with gh deficiency: a single-center experience. |
2015-02-10 |
2023-08-13 |
human |
| Pinaki Dutta, Bhuvanesh Mahendran, K S Reddy, Jasmina Ahluwalia, Kim Vaiphei, R K Kochhar, Prakamya Gupta, Anand Srinivasan, Mahesh Prakash, Kanchan Kumar Mukherjee, V N Shah, Girish Parthan, Anil Bhansal. Short-term efficacy of recombinant human GH therapy in cured acromegaly patients with GH deficiency: a single-center experience. Endocrine connections. vol 4. issue 1. 2015-02-10. PMID:25600246. |
the effectiveness and short-term safety of recombinant human gh (r-hgh) in acromegaly patients with gh deficiency (ghd) after treatment are not well established. |
2015-02-10 |
2023-08-13 |
human |